Eli Lilly and Company LLY today
announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients
with non-small cell lung cancer (NSCLC). Results were presented today during
the Lung Cancer - Metastatic Poster Session at the ESMO 2012 Congress (European
Society for Medical Oncology), 1:00 p.m. - 2:00 p.m. CET, in Vienna, Austria.
Interim data for a study in chemotherapy-näive patients with advanced NSCLC
treated with ramucirumab in combination with first-line ALIMTA® (pemetrexed
for
injection)/platinum-based chemotherapy (Abstract #1245) and final data for a
study in patients treated with ramucirumab in combination with paclitaxel/
carboplatinum chemotherapy (Abstract#1287) were presented. The pre-specified
interim analysis of progression-free survival (PFS) (Abstract #1245) and final
six-month PFS rate (Abstract #1287) support continued development of
ramucirumab in lung cancer.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in